Shares of EndoChoice Holdings Inc. (NYSE:GI) have been assigned an average broker rating score of 2.75 (Hold) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and one has assigned a strong buy recommendation to the company. EndoChoice Holdings’ rating score has declined by 57.1% from three months ago as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 12-month consensus price objective of $7.50 for the company and are expecting that the company will post ($0.52) earnings per share for the current quarter, according to Zacks. Zacks has also assigned EndoChoice Holdings an industry rank of 155 out of 265 based on the ratings given to its competitors.
Several equities research analysts have recently weighed in on the company. William Blair reissued a “market perform” rating on shares of EndoChoice Holdings in a research note on Friday, September 30th. Stifel Nicolaus decreased their price target on EndoChoice Holdings from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, August 4th. JPMorgan Chase & Co. cut EndoChoice Holdings from an “overweight” rating to a “neutral” rating in a research note on Thursday, August 4th. Finally, Zacks Investment Research cut EndoChoice Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd.
A number of large investors have recently added to or reduced their stakes in the company. Paloma Partners Management Co acquired a new stake in EndoChoice Holdings during the second quarter valued at approximately $161,000. Emerald Acquisition Ltd. acquired a new stake in EndoChoice Holdings during the second quarter valued at approximately $215,000. Spark Investment Management LLC acquired a new stake in EndoChoice Holdings during the second quarter valued at approximately $318,000. Bridgeway Capital Management Inc. acquired a new stake in EndoChoice Holdings during the second quarter valued at approximately $368,000. Finally, State Street Corp boosted its stake in EndoChoice Holdings by 46.7% in the first quarter. State Street Corp now owns 76,915 shares of the company’s stock valued at $402,000 after buying an additional 24,500 shares in the last quarter. 38.67% of the stock is owned by institutional investors and hedge funds.
Shares of EndoChoice Holdings (NYSE:GI) opened at 7.97 on Friday. The firm has a 50-day moving average price of $5.37 and a 200 day moving average price of $4.90. EndoChoice Holdings has a 1-year low of $3.64 and a 1-year high of $12.06. The company’s market cap is $207.59 million.
EndoChoice Holdings (NYSE:GI) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.47. The firm earned $19.30 million during the quarter, compared to the consensus estimate of $20.67 million. EndoChoice Holdings had a negative net margin of 88.94% and a negative return on equity of 62.04%. EndoChoice Holdings’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.01) earnings per share. On average, equities analysts anticipate that EndoChoice Holdings will post ($2.53) earnings per share for the current year.
About EndoChoice Holdings
EndoChoice Holdings, Inc is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EndoChoice Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EndoChoice Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.